| HOME >> BIOLOGY >> TECHNOLOGY |
2,3353,086Current portion of deferred revenue
8,4188,176Current portion of notes payable
161-Total current liabilities
62,08869,714Long-term portion of deferred revenue
2,2002,003Notes payable, less current portion
1,623-Other liabilities
4,2683,120Total liabilities
70,17974,837Shareholders' equity:Common stock
345,302324,211Additional paid-in capital
104,73293,144Accumulated other comprehensive income
17333Accumulated deficit
(209,946)(205,555)Total shareholders' equity
240,261211,833Total liabilities and shareholders' equity
$
310,440$ 286,670 CEPHEIDCONDENSED CONSOLIDATED UNAUDITED STATEMENTS OF CASH FLOWS(in thousands)Six Months Ended June 30,20122011Cash flows from operating activities:Net income (loss)
$ (4,391)$
2,354Adjustments to reconcile net income (loss) to net cash used in operating activities:Depreciation and amortization of property and equipment
6,3085,031Amortization of intangible assets
2,6333,452Stock-based compensation related to employees and consulting services rendered
11,5679,343Changes in operating assets and liabilities:Accounts receivable
761(3,527)Inventory
(5,950)(7,650)Prepaid expenses and other current assets
(7,475)(1,440)Other non-current assets
(105)(74)Accounts payable and other current liabilities
(12,233)2,145Accrued compensation
(1,312)1,069Deferred revenue
43813Net cash provided by (used in) operating activities
(9,759)10,716Cash flows from investing activities:Capital expenditures
(11,168)(6,974)Payments for technology license
-(1,000)Cost of acquisitions, net
(17,462)(296)Net cash used in investing activities
(28,630)(
'/>"/>
| SOURCE Cepheid Copyright©2012 PR Newswire. All rights reserved |